Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2024, Cilt: 51 Sayı: 2, 223 - 231, 14.06.2024
https://doi.org/10.5798/dicletip.1501288

Öz

Kaynakça

  • 1.Tanai, Edit, and Stefan Frantz. Pathophysiology ofheart failure. Compr Physiol. 2015; 6(1): 187-214.
  • 2.Ziaeian B, Fonarow GC. Epidemiology andaetiology of heart failure. Nat Rev Cardiol. 2016;13(6): 368-78.
  • 3.Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failureand subsequent survival between 1986 and 2003: apopulation study of 5.1 million people. Circulation.2009; 119(4): 515-23.
  • 4.McDonagh TA, Metra M, Adamo M, et al. 2021 ESCGuidelines for the diagnosis and treatment of acuteand chronic heart failure. Eur Heart J. 2021; 42(36):3599-726.
  • 5.Zaya, M., Phan, A., Schwarz, E. R. Predictors of re-hospitalization in patients with chronic heart failure. World journal of cardiology. 2012; 4(2): 23.
  • 6.Ezekowitz, J. A., O'Meara, E., McDonald, M., et al.2017 Comprehensive update of the CanadianCardiovascular Society guidelines for themanagement of heart failure. Canadian Journal ofCardiology. 2017; 33(11): 1342-433.
  • 7.Bonilla-Palomas JL, Gamez-Lopez AL, Moreno-Conde M, et al. Hypoalbuminemia in acute heartfailure patient: causes and its impact on hospital and long term mortality. J Card Fil. 2014; 20: 350-8.
  • 8.Carubelli V, Metra M, Lombardi C, et al. Renaldysfunction in acute heart failure: epidemiology,mechanisms and assessment. Heart Fail Rev. 2012;17: 271-82.
  • 9.Butler J, Chirovsky D, Phatak H, et al. Renalfunction, health outcomes, and resource utilizationin acute heart failure: a systematic review. CircHeart Fail. 2010; 3: 726-45.
  • 10.Khan H., Kunutsor S., Kalogeropoulos A. P.,et al.Resting heart rate and risk of incident heart failure:three prospective cohort studies and a systematicmeta‐analysis. Journal of the American HeartAssociation. 2015; 4(1); e001364.
  • 11.McMurray J. J., Adamopoulos S., Anker S. D., et al.ESC Guidelines for the diagnosis and treatment ofacute and chronic heart failure 2012: The Task Forcefor the Diagnosis and Treatment of Acute andChronic Heart Failure 2012 of the European Societyof Cardiology. Developed in collaboration with theHeart Failure Association (HFA) of the ESC.European heart journal. 2012; 33(14); 1787-847.
  • 12.Azad N, Lemay G. Management of chronic heartfailure in the older population. J GeriatrCardiol.2014; 11(4): 329-37.
  • 13.Wehbe RM, Khan SS, Shah SJ, Ahmad FS.Predicting High-Risk Patients and High-RiskOutcomes in Heart Failure. Heart Fail Clin. 2020;16(4): 387-407.
  • 14.Jackson CE, Bezlyak V, Tsorlalis IK, et al.Multimarker laboratory testing in acutedecompensated heart failure (ADHF)- how muchprognostic information do novel biomarkers BNP, troponin and CRP provide in addition to routine laboratory tests?.Eur Heart J. 2009; 3: 711.
  • 15.Polat N, Aydın M,Yıldız A, et al. The prognosticsignificance of human serum albumin in patient with acutdecompansated systolic hearth failure.ActaCardiol. 2014; 69(6): 648-54.
  • 16.Allen LA, Felker GM, Pocock S,et al. CHARMInvestigators. Liver function abnormalities andoutcome in patients with chronic heart failure: datafrom the Candesartan in Heart Failure: Assessmentof Reduction in Mortality and Morbidity (CHARM)program. Eur J Heart Fail. 2009; 11: 170e7.
  • 17.Horwich TB, Kalantar-Zadeh K, MacLellan RW, etal. Albumin levels predict survival in patients withsystolic heart failure. Am Heart J. 2008;155: 883e9.
  • 18.Novack V, Pencina M, Zahger D, et al. Routinelaboratory results and thirty day and one-yearmortality risk following hospitalization with acutedecompensated heart failure. PLoS ONE. 2010; 5:e12184.
  • 19.Costanzo MR. The Cardiorenal Syndrome inHeart Failure. Heart Fail Clin. 2020; 16(1): 81-97.
  • 20.Giamouzis G, Butler J, Triposkiadis F. Renalfunction in advanced heart failure. Congest HeartFail. 2011; 17: 180–8.
  • 21.Khan, F., Ali, J., Sajjad, W., et al. Heart FailureReadmissions: A Deep Dive into PatientDemographics, Comorbidities, and SystemicChallenges. Journal of Health and RehabilitationResearch.2023; 3(2): 635-39.
  • 22.Vidán MT, Blaya-Novakova V, Sánchez E, et al.Prevalence and prognostic impact of frailty and itscomponents in non-dependent elderly patientswithheart failure. Eur J Heart Fail. 2016; 18(7): 869-75.
  • 23.Konishi M, Haraguchi G, Ohigashi H, et al.Progression of hyponatremia is associated withincreased cardiac mortality in patients hospitalizedfor acute decompensated heart failure. J Card Fail.2012; 18(8): 620-5.
  • 24.Donzé JD, Beeler PE, Bates DW. Impact ofHyponatremia Correction on the Risk for 30-DayReadmission and Death in Patients with CongestiveHeart Failure. Am J Med. 2016; 129(8): 836-42.
  • 25.Shah R, Agarwal AK. Anemia associated withchronic heart failure: current concepts. ClinIntervAging. 2013; 8: 111-22.

Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients

Yıl 2024, Cilt: 51 Sayı: 2, 223 - 231, 14.06.2024
https://doi.org/10.5798/dicletip.1501288

Öz

Aim: Despite medical advancements, heart failure (HF) maintains high mortality rates. Our research delves into examining the relationship between the serum creatinine/albumin ratio and one-year mortality in patients with decompensated systolic HF.
Methods: During the period from October 2014 to October 2015, we enrolled 80 patients (comprising 37 females) who had been diagnosed with acute systolic decompensated heart failure and had a left ventricular ejection fraction (LVEF) of ≤ 40%. These patients were divided into two cohorts depending on whether they experienced all-cause mortality within the span of one year.
Results: Among the 80 participants, 31 (39%) experienced mortality within the first year. The average age of the deceased group was 69±14 years, with 38.7% (n=12) being female. In contrast, the surviving group had an average age of 66±12 years, with 51% (n=25) being female. The HF group with mortality exhibited significantly higher levels of serum creatinine-albumin ratio, urea, and creatinine values, along with a higher prevalence of pretibial edema (p<0.01).Furthermore, the deceased HF group exhibited significantly lower LVEF, albumin levels, lymphocyte counts, and systolic and diastolic blood pressure values. Statistical analysis revealed a significant difference in the serum creatinine/albumin ratio between the deceased group (0.68±0.27) and the surviving group (0.38±0.18), with a p-value of less than 0.01. Using a cut-off value of 0.45 for the creatinine/albumin ratio, the sensitivity and specificity for predicting one-year mortality in HF patients were 81% and 78% , respectively.
Conclusion: The conjunction of heightened creatinine levels, diminished albumin levels, and an augmented creatinine/albumin ratio could potentially function as straightforward, economical prognostic indicators for forecasting one-year mortality in systolic decompensated HF patients.

Kaynakça

  • 1.Tanai, Edit, and Stefan Frantz. Pathophysiology ofheart failure. Compr Physiol. 2015; 6(1): 187-214.
  • 2.Ziaeian B, Fonarow GC. Epidemiology andaetiology of heart failure. Nat Rev Cardiol. 2016;13(6): 368-78.
  • 3.Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failureand subsequent survival between 1986 and 2003: apopulation study of 5.1 million people. Circulation.2009; 119(4): 515-23.
  • 4.McDonagh TA, Metra M, Adamo M, et al. 2021 ESCGuidelines for the diagnosis and treatment of acuteand chronic heart failure. Eur Heart J. 2021; 42(36):3599-726.
  • 5.Zaya, M., Phan, A., Schwarz, E. R. Predictors of re-hospitalization in patients with chronic heart failure. World journal of cardiology. 2012; 4(2): 23.
  • 6.Ezekowitz, J. A., O'Meara, E., McDonald, M., et al.2017 Comprehensive update of the CanadianCardiovascular Society guidelines for themanagement of heart failure. Canadian Journal ofCardiology. 2017; 33(11): 1342-433.
  • 7.Bonilla-Palomas JL, Gamez-Lopez AL, Moreno-Conde M, et al. Hypoalbuminemia in acute heartfailure patient: causes and its impact on hospital and long term mortality. J Card Fil. 2014; 20: 350-8.
  • 8.Carubelli V, Metra M, Lombardi C, et al. Renaldysfunction in acute heart failure: epidemiology,mechanisms and assessment. Heart Fail Rev. 2012;17: 271-82.
  • 9.Butler J, Chirovsky D, Phatak H, et al. Renalfunction, health outcomes, and resource utilizationin acute heart failure: a systematic review. CircHeart Fail. 2010; 3: 726-45.
  • 10.Khan H., Kunutsor S., Kalogeropoulos A. P.,et al.Resting heart rate and risk of incident heart failure:three prospective cohort studies and a systematicmeta‐analysis. Journal of the American HeartAssociation. 2015; 4(1); e001364.
  • 11.McMurray J. J., Adamopoulos S., Anker S. D., et al.ESC Guidelines for the diagnosis and treatment ofacute and chronic heart failure 2012: The Task Forcefor the Diagnosis and Treatment of Acute andChronic Heart Failure 2012 of the European Societyof Cardiology. Developed in collaboration with theHeart Failure Association (HFA) of the ESC.European heart journal. 2012; 33(14); 1787-847.
  • 12.Azad N, Lemay G. Management of chronic heartfailure in the older population. J GeriatrCardiol.2014; 11(4): 329-37.
  • 13.Wehbe RM, Khan SS, Shah SJ, Ahmad FS.Predicting High-Risk Patients and High-RiskOutcomes in Heart Failure. Heart Fail Clin. 2020;16(4): 387-407.
  • 14.Jackson CE, Bezlyak V, Tsorlalis IK, et al.Multimarker laboratory testing in acutedecompensated heart failure (ADHF)- how muchprognostic information do novel biomarkers BNP, troponin and CRP provide in addition to routine laboratory tests?.Eur Heart J. 2009; 3: 711.
  • 15.Polat N, Aydın M,Yıldız A, et al. The prognosticsignificance of human serum albumin in patient with acutdecompansated systolic hearth failure.ActaCardiol. 2014; 69(6): 648-54.
  • 16.Allen LA, Felker GM, Pocock S,et al. CHARMInvestigators. Liver function abnormalities andoutcome in patients with chronic heart failure: datafrom the Candesartan in Heart Failure: Assessmentof Reduction in Mortality and Morbidity (CHARM)program. Eur J Heart Fail. 2009; 11: 170e7.
  • 17.Horwich TB, Kalantar-Zadeh K, MacLellan RW, etal. Albumin levels predict survival in patients withsystolic heart failure. Am Heart J. 2008;155: 883e9.
  • 18.Novack V, Pencina M, Zahger D, et al. Routinelaboratory results and thirty day and one-yearmortality risk following hospitalization with acutedecompensated heart failure. PLoS ONE. 2010; 5:e12184.
  • 19.Costanzo MR. The Cardiorenal Syndrome inHeart Failure. Heart Fail Clin. 2020; 16(1): 81-97.
  • 20.Giamouzis G, Butler J, Triposkiadis F. Renalfunction in advanced heart failure. Congest HeartFail. 2011; 17: 180–8.
  • 21.Khan, F., Ali, J., Sajjad, W., et al. Heart FailureReadmissions: A Deep Dive into PatientDemographics, Comorbidities, and SystemicChallenges. Journal of Health and RehabilitationResearch.2023; 3(2): 635-39.
  • 22.Vidán MT, Blaya-Novakova V, Sánchez E, et al.Prevalence and prognostic impact of frailty and itscomponents in non-dependent elderly patientswithheart failure. Eur J Heart Fail. 2016; 18(7): 869-75.
  • 23.Konishi M, Haraguchi G, Ohigashi H, et al.Progression of hyponatremia is associated withincreased cardiac mortality in patients hospitalizedfor acute decompensated heart failure. J Card Fail.2012; 18(8): 620-5.
  • 24.Donzé JD, Beeler PE, Bates DW. Impact ofHyponatremia Correction on the Risk for 30-DayReadmission and Death in Patients with CongestiveHeart Failure. Am J Med. 2016; 129(8): 836-42.
  • 25.Shah R, Agarwal AK. Anemia associated withchronic heart failure: current concepts. ClinIntervAging. 2013; 8: 111-22.
Toplam 25 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi, Tıp Eğitimi
Bölüm Original Articles
Yazarlar

Mehmet Ali Işık

Adem Aktan

Tuncay Güzel

Raif Kılıç

Muhammed Demir

Serhat Günlü

Fethullah Kayan Bu kişi benim

Mehmet Zülkif Karahan

Mehmet Özbek

Abdulkadir Arpa

Nihat Polat Bu kişi benim

Murat Yüksel

Yayımlanma Tarihi 14 Haziran 2024
Gönderilme Tarihi 14 Eylül 2023
Yayımlandığı Sayı Yıl 2024 Cilt: 51 Sayı: 2

Kaynak Göster

APA Işık, M. A., Aktan, A., Güzel, T., Kılıç, R., vd. (2024). Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients. Dicle Tıp Dergisi, 51(2), 223-231. https://doi.org/10.5798/dicletip.1501288
AMA Işık MA, Aktan A, Güzel T, Kılıç R, Demir M, Günlü S, Kayan F, Karahan MZ, Özbek M, Arpa A, Polat N, Yüksel M. Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients. diclemedj. Haziran 2024;51(2):223-231. doi:10.5798/dicletip.1501288
Chicago Işık, Mehmet Ali, Adem Aktan, Tuncay Güzel, Raif Kılıç, Muhammed Demir, Serhat Günlü, Fethullah Kayan, Mehmet Zülkif Karahan, Mehmet Özbek, Abdulkadir Arpa, Nihat Polat, ve Murat Yüksel. “Admission Serum Creatinine/Albumin Ratio and Its Relationship With 1-Year Mortality in Decompensated Heart Failure Patients”. Dicle Tıp Dergisi 51, sy. 2 (Haziran 2024): 223-31. https://doi.org/10.5798/dicletip.1501288.
EndNote Işık MA, Aktan A, Güzel T, Kılıç R, Demir M, Günlü S, Kayan F, Karahan MZ, Özbek M, Arpa A, Polat N, Yüksel M (01 Haziran 2024) Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients. Dicle Tıp Dergisi 51 2 223–231.
IEEE M. A. Işık, “Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients”, diclemedj, c. 51, sy. 2, ss. 223–231, 2024, doi: 10.5798/dicletip.1501288.
ISNAD Işık, Mehmet Ali vd. “Admission Serum Creatinine/Albumin Ratio and Its Relationship With 1-Year Mortality in Decompensated Heart Failure Patients”. Dicle Tıp Dergisi 51/2 (Haziran 2024), 223-231. https://doi.org/10.5798/dicletip.1501288.
JAMA Işık MA, Aktan A, Güzel T, Kılıç R, Demir M, Günlü S, Kayan F, Karahan MZ, Özbek M, Arpa A, Polat N, Yüksel M. Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients. diclemedj. 2024;51:223–231.
MLA Işık, Mehmet Ali vd. “Admission Serum Creatinine/Albumin Ratio and Its Relationship With 1-Year Mortality in Decompensated Heart Failure Patients”. Dicle Tıp Dergisi, c. 51, sy. 2, 2024, ss. 223-31, doi:10.5798/dicletip.1501288.
Vancouver Işık MA, Aktan A, Güzel T, Kılıç R, Demir M, Günlü S, Kayan F, Karahan MZ, Özbek M, Arpa A, Polat N, Yüksel M. Admission Serum Creatinine/Albumin Ratio and its Relationship with 1-Year Mortality in Decompensated Heart Failure Patients. diclemedj. 2024;51(2):223-31.